Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8458623 | Radiotherapy and Oncology | 2018 | 6 Pages |
Abstract
Re-RT after re-Op was tolerable with a cumulative median EQD2 of 99.3â¯Gy and resulted in clear benefit in PFS and marginal gain in OS. Survival gain with re-Op/RT was more prominent in patients with two or more risk factors (age â¥50, WHO pathologic grade IV, unmethylated MGMT promoter), and needs to be validated.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Seok-Joo Chun, Sung-Hye Park, Chul-Kee Park, Jin Wook Kim, Tae Min Kim, Seung Hong Choi, Soon-Tae Lee, Il Han Kim,